размер рынка и исследование лечения простого герпеса (вирус Hsv 1) к 2031 году

Global Cold Sore Treatment For Hsv 1 Virus Market

Размер рынка в млрд долларов США

CAGR : 6.60 %

Прогнозируемый период	2024 –2031
Размер рынка (базовый год)	USD 927.29 Million
Размер рынка (прогнозируемый год)	USD 1,501.88 Million
CAGR	6.60 %
Основные игроки рынка	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Запрос на разблокировку

>Глобальный рынок лечения герпеса на губах (вируса HSV 1), по типу лечения (лекарственные препараты, прикладные продукты, пластыри от герпеса на губах и другие (немедикаментозные продукты)), способу введения (перорально, местно и другие), способу покупки (безрецептурные и рецептурные препараты), типу штамма (вирус простого герпеса 1 типа и вирус простого герпеса 2 типа), типу препарата (дженерики и брендовые), типу населения (взрослые, педиатрия и гериатрия), полу (женщины и мужчины), конечному пользователю (домашний уход, больницы, специализированные клиники и другие), каналу сбыта (прямые тендеры, розничные продажи и другие) — отраслевые тенденции и прогноз до 2031 года.

Анализ и размер рынка лечения герпеса (вируса HSV 1)

Ожидается, что мировой рынок средств для лечения герпеса (вируса герпеса 1 типа) будет расти в прогнозируемый период с 2024 по 2031 год.

Глобальный рынок лечения герпеса (вируса HSV 1) обусловлен высокой распространенностью как вирусов HSV-1, так и вирусов H11, что является основным фактором развития глобального рынка лечения герпеса (вируса HSV 1). HSV-1 широко распространен, по оценкам, им заражено 67% населения мира в возрасте до 50 лет. Аналогичным образом, инфекции H11 распространены среди домашних птиц и иногда передаются людям.

Такая распространенность обуславливает спрос на эффективное лечение. Люди с HSV-1 или H11 часто сталкиваются с рецидивирующими вспышками герпеса, которые могут быть болезненными и некрасивыми. Это создает сильный потребительский спрос на лечение, которое может облегчить симптомы, снизить частоту вспышек и предотвратить передачу. Изменение образа жизни, включая повышенный стресс, усталость и пребывание на солнце, может спровоцировать вспышки. Стареющее население также более восприимчиво к герпесу, что способствует более высоким показателям инфицирования.

Компания Data Bridge Market Research анализирует, что мировой рынок средств для лечения герпеса (вируса HSV 1) растет со среднегодовым темпом роста 6,6% в прогнозируемый период с 2024 по 2031 год и, как ожидается, достигнет 1 501,88 млн долларов США к 2031 году по сравнению с 927,29 млн долларов США в 2023 году.

Отчет Метрика	Подробности
Прогнозируемый период	2024-2031
Базовый год	2023
Исторические годы	2022 (настраиваемый 2016-2021)
Количественные единицы	Доход в млн. долл. США
Охваченные сегменты	Тип лечения (лекарственные средства, прикладные продукты, пластыри от герпеса на губах и другие (немедикаментозные продукты)), способ применения (пероральный, местный и другие), способ приобретения (безрецептурные и рецептурные препараты ), тип штамма (вирус простого герпеса 1-го типа и вирус простого герпеса 2-го типа), тип препарата (дженерики и брендовые), тип популяции (взрослые, педиатрия и гериатрия), пол (женский и мужской), конечный пользователь ( домашняя медицинская помощь , больницы, специализированные клиники и другие), канал распространения (прямые тендеры, розничные продажи и другие)
Страны, охваченные	США, Канада и Мексика, Великобритания, Германия, Франция, Испания, Италия, Бельгия, Россия, Швейцария, Нидерланды, Турция и остальная Европа, Китай, Австралия, Япония, Индия, Сингапур, Южная Корея, Малайзия, Таиланд, Индонезия, Филиппины и остальная часть Азиатско-Тихоокеанского региона, Бразилия, Аргентина и остальная часть Южной Америки, Южная Африка, Египет, Саудовская Аравия, ОАЭ и остальная часть Ближнего Востока и Африки
Охваченные участники рынка	Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies и Devirex AG среди прочих

Определение рынка

ВПГ-1, или вирус простого герпеса типа 1, является распространенным вирусом, вызывающим герпес на губах и вокруг рта. Эти язвы представляют собой заполненные жидкостью волдыри, которые могут быть болезненными и могут сохраняться около 7-10 дней.

Лечение герпеса обычно включает противовирусные препараты, такие как ацикловир, фамцикловир или валацикловир, которые могут помочь уменьшить тяжесть и продолжительность вспышек. Безрецептурные кремы и мази, такие как содержащие докозанол или бензиловый спирт , также могут облегчить симптомы. Содержание пораженной области в чистоте и избегание триггеров, таких как стресс или воздействие солнца, может помочь предотвратить вспышки.

Динамика мирового рынка лечения герпеса (вируса HSV 1)

В этом разделе рассматривается понимание рыночных драйверов, преимуществ, возможностей, ограничений и проблем. Все это подробно обсуждается ниже:

Драйверы

Растущая распространенность инфекции герпеса

Растущая распространенность инфекций герпеса, вызванная изменением образа жизни, старением населения, повышением осведомленности и глобализацией, является ключевым фактором мирового рынка лечения герпеса (вируса HSV 1). Ожидается, что эта тенденция сохранится, что приведет к дальнейшим инновациям и разработке новых вариантов лечения для людей, страдающих этими инфекциями.

Растущая осведомленность о симптомах герпеса и вариантах лечения

Возросшая доступность информации о герпесе через различные медиаканалы, такие как интернет, социальные сети и кампании в области здравоохранения, повысила осведомленность о признаках и симптомах герпеса. Эта возросшая осведомленность привела к тому, что больше людей стали обращаться за медицинской помощью и лечением герпеса, что в свою очередь стимулировало рост рынка.

Возможность

Растущий прогресс в лечении инфекций, вызванных герпесом

Прорывы в лечении инфекций, вызванных вирусом герпеса (HSV-1) и опоясывающего лишая (вирус ветряной оспы), привели к разработке более мощных противовирусных препаратов с меньшим количеством побочных эффектов. Инновационные системы доставки лекарств, такие как липосомальные формулы, повысили эффективность лечения и приверженность пациентов.

Сдержанность/Вызов

Возрастающая сложность разработки вакцин

Разработка вакцины для лечения герпеса, вызванного вирусом HSV-1, сталкивается со значительными препятствиями. Одной из таких проблем является способность вируса устанавливать латентность в нервных ганглиях, что затрудняет его вакцинацию, поскольку он остается спящим в неактивных вирусных резервуарах. Кроме того, механизмы уклонения HSV-1 от иммунного ответа затрудняют индукцию сильного и стойкого иммунного ответа посредством вакцинации. Несмотря на эти проблемы, постоянные исследования и инновации имеют решающее значение для продвижения разработки вакцин и снижения бремени инфекций HSV-1 во всем мире.

Последние события

В августе 2019 года Sun Pharmaceutical Industries Ltd. сообщила, что одна из ее дочерних компаний уступила лицензионное соглашение дочерней компании China Medical System Holding Ltd. на разработку и коммерциализацию 7 дженериков в Китае. Это соглашение помогает компании расширить свой бизнес и сделать профиль продукта сильным
В ноябре 2020 года Amneal Pharmaceuticals LLC объявила об одобрении FDA своей сокращенной заявки на новый препарат (ANDA) для крема Ацикловир, 5%. Это дженерик Зовиракса для лечения герпеса губ у подростков. Инициатива компании приведет к увеличению дистрибуции продукта, повышению узнаваемости бренда и росту продаж. Это приведет к положительному росту рынка
В августе 2020 года GSK завершила сделку по приобретению Affinivax, Inc. объявила о завершении сделки по приобретению Affinivax, Inc. (Affinivax), базирующейся в Кембридже, штат Массачусетс, биофармацевтической компании клинической стадии. Пневмококковые вакцины следующего поколения являются наиболее разработанными из нового класса вакцин, которые Affinivax возглавляет в разработке пневмококковых вакцин следующего поколения

Мировой рынок лечения герпеса (вируса HSV 1)

Глобальный рынок лечения герпеса (вируса HSV 1) сегментирован на девять заметных сегментов на основе типа лечения, пути введения, способа покупки, типа штамма, типа препарата, типа популяции, пола, конечного пользователя и канала сбыта. Рост среди сегментов помогает вам анализировать нишевые очаги роста и стратегии для выхода на рынок и определять ваши основные области применения и различия в ваших целевых рынках.

Тип лечения

Лекарства
Прикладные продукты
Пластыри от герпеса
Другие (нелекарственные продукты)

По типу лечения мировой рынок средств для лечения герпеса (вируса ВПГ 1) сегментируется на лекарственные препараты, аппликационные средства, пластыри от герпеса и прочие (немедикаментозные средства).

Путь введения

Оральный
Актуальный
Другие

В зависимости от способа применения мировой рынок средств для лечения герпеса (вируса ВПГ-1) сегментируется на пероральные, местные и прочие.

Способ покупки

Без рецепта
Лекарства, отпускаемые по рецепту

По способу приобретения мировой рынок средств для лечения герпеса (вируса герпеса 1 типа) сегментирован на безрецептурные и рецептурные препараты.

Тип штамма

Вирус простого герпеса 1 типа
Вирус простого герпеса 2 типа

На основе типа штамма мировой рынок средств для лечения герпеса (вируса ВПГ 1) сегментирован на вирус простого герпеса 1 типа и вирус простого герпеса 2 типа.

Тип препарата

Общий
Фирменный

По типу препарата мировой рынок средств для лечения герпеса (вируса ВПГ-1) сегментируется на дженерики и брендовые препараты.

Тип населения

Взрослые
Педиатрия
Гериатрия

В зависимости от типа населения мировой рынок средств для лечения герпеса (вируса ВПГ-1) сегментируется на взрослую, педиатрическую и гериатрическую группы.

Пол

Женский
Мужской

По половому признаку мировой рынок средств для лечения герпеса (вируса герпеса 1 типа) сегментирован на женский и мужской.

Конечный пользователь

Медицинская помощь на дому
Больницы
Специализированные клиники
Другие

По признаку конечного пользователя мировой рынок лечения герпеса (вируса герпеса 1 типа) сегментируется на услуги по уходу на дому, больницы, специализированные клиники и другие.

Канал распространения

Прямые тендеры
Розничные продажи
Другие

По каналам сбыта мировой рынок средств для лечения герпеса (вируса герпеса 1 типа) сегментируется на прямые торги, розничные продажи и другие.

Региональный анализ/информация о мировом рынке лечения герпеса (вируса HSV 1)

Проведен анализ мирового рынка средств для лечения герпеса (вируса герпеса 1 типа), а также предоставлены сведения о размерах рынка и тенденциях на основе типа лечения, пути введения, способа покупки, типа штамма, типа препарата, типа населения, пола, конечного пользователя и канала сбыта, как указано выше.

Страны, охваченные данным отчетом о мировом рынке средств для лечения герпеса (вируса HSV 1): США, Канада и Мексика, Великобритания, Германия, Франция, Испания, Италия, Бельгия, Россия, Швейцария, Нидерланды, Турция и остальные страны Европы, Китай, Австралия, Япония, Индия, Сингапур, Южная Корея, Малайзия, Таиланд, Индонезия, Филиппины и остальные страны Азиатско-Тихоокеанского региона, Бразилия, Аргентина и остальные страны Южной Америки, Южная Африка, Египет, Саудовская Аравия, ОАЭ и остальные страны Ближнего Востока и Африки.

Ожидается, что Северная Америка будет доминировать на мировом рынке лечения герпеса (вируса HSV 1) благодаря таким факторам, как высокая распространенность герпеса, развитая инфраструктура здравоохранения, высокая осведомленность потребителей и покупательная способность, постоянные инициативы в области исследований и разработок, налаженные сети маркетинга и дистрибуции, а также снижение стигматизации, связанной с обращением за лечением.

Ожидается, что США будут доминировать на североамериканском рынке средств для лечения герпеса (вируса HSV 1) из-за таких факторов, как большая численность населения, высокие расходы на здравоохранение, сложная система здравоохранения, обширная фармацевтическая промышленность, а также широкая осведомленность потребителей и доступность средств для лечения герпеса.

Ожидается, что Германия будет доминировать на европейском рынке лечения герпеса (вируса HSV 1) благодаря своей развитой инфраструктуре здравоохранения, значительному потребительскому спросу на средства от герпеса, сильной фармацевтической промышленности, обширным исследованиям и разработкам, а также хорошо налаженным дистрибьюторским сетям, что делает ее центром инноваций и доступности в лечении герпеса.

Ожидается, что Китай будет доминировать на рынке лечения герпеса (вируса HSV 1) в Азиатско-Тихоокеанском регионе из-за большой численности населения, растущих расходов на здравоохранение, расширения фармацевтической промышленности, растущей осведомленности потребителей и спроса на средства лечения герпеса в сочетании с развивающейся инфраструктурой здравоохранения и растущей распространенностью герпеса.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка, которые влияют на текущие и будущие тенденции рынка. Такие данные, как анализ цепочки создания стоимости сверху и снизу, технические тенденции и анализ пяти сил Портера, тематические исследования, являются некоторыми из указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам учитываются наличие и доступность глобальных брендов и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, влияние внутренних тарифов и торговых путей.

Конкурентная среда и глобальный анализ доли рынка лечения герпеса (вируса HSV 1)

Конкурентная среда мирового рынка лечения герпеса (вируса HSV 1) содержит подробную информацию по конкурентам. Включены следующие сведения: обзор компании, финансовые показатели компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, глобальное присутствие, производственные площадки и объекты, производственные мощности, сильные и слабые стороны компании, запуск продукта, широта и широта продукта и доминирование в применении. Приведенные выше данные относятся только к фокусу компаний на мировом рынке лечения герпеса (вируса HSV 1).

Некоторые из основных игроков, работающих на мировом рынке лечения герпеса (вируса HSV 1), включают Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies и Devirex AG и другие.

SKU-72547

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Интерактивная панель анализа данных
Панель анализа компании для возможностей с высоким потенциалом роста
Доступ аналитика-исследователя для настройки и запросов
Анализ конкурентов с помощью интерактивной панели
Последние новости, обновления и анализ тенденций
Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов

Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: REGULATIONS

5.1 REGULATION IN U.S.:

5.2 REGULATION IN CANADA:

5.3 REGULATION IN SPAIN:

5.4 REGULATION IN U.K.:

5.5 REGULATION IN INDIA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING PREVALENCE OF COLD SORE INFECTION

6.1.2 GROWING AWARENESS ABOUT COLD SORE SYMPTOMS AND TREATMENT OPTIONS

6.1.3 IMPACT OF GENERIC DRUGS ON THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET

6.2 RESTRAINTS

6.2.1 DEVELOPMENT OF DRUG-RESISTANT STRAINS OF HSV-1 AND H11 VIRUSES

6.2.2 LACK OF CURATIVE TREATMENT FOR INFECTION

6.3 OPPORTUNITIES

6.3.1 RISING ADVANCEMENTS IN TREATMENTS FOR COLD SORE INFECTIONS

6.3.2 INCREASING ADOPTION OF TELEMEDICINE AND DIGITAL HEALTH SOLUTIONS

6.4 CHALLENGES

6.4.1 INCREASING COMPLEXITY OF VACCINE DEVELOPMENT

6.4.2 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS IN TREATING COLD SORE

7 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 MEDICATIONS

7.2.1 ANTIVIRAL AGENTS

7.2.2 ANALGESIC AGENTS

7.2.3 OTHERS

7.3 APPLIED PRODUCTS

7.3.1 BRANDED

7.3.2 GENERICS

7.4 COLD SORE PATCHES

7.4.1 SEMI OCCLUSIVE HYDROCOLLOID PATCH

7.4.2 FILM FORMING PATCH

7.5 OTHERS (NON MEDICATED PRODUCTS)

8 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW

8.2 ORAL

8.2.1 TABLETS

8.2.2 CAPSULES

8.2.3 OTHERS

8.3 TOPICAL

8.3.1 CREAM

8.3.2 LIP BALM

8.3.3 OTHERS

8.4 OTHERS

9 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE

9.1 OVERVIEW

9.2 OVER THE COUNTER

9.3 PRESCRIPTION DRUG

10 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE

10.1 OVERVIEW

10.2 HERPES SIMPLEX TYPE 1 VIRUS

10.3 HERPES SIMPLEX TYPE 2 VIRUS

11 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE

11.1 OVERVIEW

11.2 GENERIC

11.3 BRANDED

12 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE

12.1 OVERVIEW

12.2 ADULTS

12.3 PEDIATRICS

12.4 GERIATRICS

13 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER

13.1 OVERVIEW

13.2 FEMALE

13.3 MALE

14 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER

14.1 OVERVIEW

14.2 HOME HEALTHCARE

14.3 HOSPITALS

14.4 SPECIALTY CLINICS

14.5 OTHERS

15 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDERS

15.3 RETAIL SALES

16 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION

16.1 OVERVIEW

16.2 NORTH AMERICA

16.2.1 U.S.

16.2.2 CANADA

16.2.3 MEXICO

16.3 EUROPE

16.3.1 GERMANY

16.3.2 FRANCE

16.3.3 U.K.

16.3.4 ITALY

16.3.5 SPAIN

16.3.6 RUSSIA

16.3.7 SWITZERLAND

16.3.8 NETHERLAND

16.3.9 TURKEY

16.3.10 BELGIUM

16.3.11 REST OF EUROPE

16.4 ASIA-PACIFIC

16.4.1 CHINA

16.4.2 JAPAN

16.4.3 INDIA

16.4.4 AUSTRALIA

16.4.5 SOUTH KOREA

16.4.6 SINGAPORE

16.4.7 MALAYSIA

16.4.8 PHILIPPINES

16.4.9 INDONESIA

16.4.10 THAILAND

16.4.11 REST OF ASIA-PACIFIC

16.5 SOUTH AMERICA

16.5.1 BRAZIL

16.5.2 ARGENTINA

16.5.3 REST OF SOUTH AMERICA

16.6 MIDDLE EAST AND AFRICA

16.6.1 SOUTH AFRICA

16.6.2 EGYPT

16.6.3 SAUDI ARABIA

16.6.4 U.A.E.

17 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.3 COMPANY SHARE ANALYSIS: EUROPE

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 FRESENIUS SE & CO. KGAA

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 ZYDUS PHARMACEUTICALS INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 COMPANY SHARE ANALYSIS

19.2.3 PRODUCT PORTFOLIO

19.2.4 RECENT DEVELOPMENT

19.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 NOVARTIS AG

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 SUN PHARMACEUTICALS INDUSTRIES LIMITED

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 AMNEAL PHARMACEUTICALS LLC

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 AMPARO MEDICAL TECHNOLOGIES

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 APOTEX INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 BLISTEX INC.

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 CARMA LABS INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 CHURCH & DWIGHT CO., INC.

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 DEVIREX AG

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 FOCUS CONSUMER HEALTHCARE

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 GSK PLC.

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENT

19.15 HALEON GROUP OF COMPANIES

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 HETERO HEALTH CARE LIMITED

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 HIKMA PHARMACEUTICALS PLC

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENT

19.18 QUANTUM HEALTH

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 URGO MEDICAL

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

19.2 VIATRIS INC.

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Список таблиц

TABLE 1 TREATMENT OF PEDIATRIC HSV INFECTIONS

TABLE 2 TREATMENT OPTIONS

TABLE 3 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 4 GLOBAL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 5 GLOBAL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 6 GLOBAL ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 7 GLOBAL ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 8 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 9 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 10 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 11 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 12 GLOBAL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 13 GLOBAL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 14 GLOBAL OTHERS (NON MEDICATED PRODUCTS) IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 15 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 16 GLOBAL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 17 GLOBAL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 18 GLOBAL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 19 GLOBAL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 20 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 21 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 22 GLOBAL OVER THE COUNTER IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 23 GLOBAL PRESCRIPTION IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 24 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE, 2022- 2031 (USD THOUSAND)

TABLE 25 GLOBAL HERPES SIMPLEX TYPE 1 VIRUS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 26 GLOBAL HERPES SIMPLEX TYPE 2 VIRUS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 27 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE, 2022- 2031 (USD THOUSAND)

TABLE 28 GLOBAL GENERIC IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 29 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 30 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031

TABLE 31 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE, 2022- 2031 (USD THOUSAND)

TABLE 32 GLOBAL ADULTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 33 GLOBAL PEDIATRICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 34 GLOBAL GERIATRICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 35 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER, 2022- 2031 (USD THOUSAND)

TABLE 36 GLOBAL FEMALE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 37 GLOBAL MALE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 38 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER, 2022- 2031 (USD THOUSAND)

TABLE 39 GLOBAL HOME HEALTHCARE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 40 GLOBAL HOSPITALS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 41 GLOBAL SPECIALTY CLINICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 42 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 43 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022- 2031 (USD THOUSAND)

TABLE 44 GLOBAL DIRECT TENDERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 45 GLOBAL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 46 GLOBAL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031

TABLE 47 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 48 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 49 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 50 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 51 NORTH AMERICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 52 NORTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 53 NORTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 54 NORTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 55 NORTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 56 NORTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 57 NORTH AMERICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 58 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 59 NORTH AMERICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 60 NORTH AMERICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 61 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 62 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 63 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 64 NORTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 66 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 67 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 68 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 69 NORTH AMERICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 70 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 71 U.S. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 72 U.S. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 73 U.S. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 74 U.S. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 75 U.S. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 76 U.S. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 77 U.S. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 78 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 79 U.S. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 80 U.S. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 81 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 82 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 84 U.S. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 85 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 86 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 87 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 88 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 89 U.S. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 91 CANADA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 92 CANADA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 93 CANADA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 94 CANADA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 95 CANADA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 96 CANADA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 97 CANADA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 98 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 99 CANADA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 100 CANADA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 101 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 102 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 103 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 104 CANADA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 106 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 107 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 108 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 109 CANADA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 110 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 MEXICO MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 112 MEXICO ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 113 MEXICO ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 114 MEXICO APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 115 MEXICO BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 116 MEXICO APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 117 MEXICO COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 118 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 119 MEXICO ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 120 MEXICO TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 121 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 122 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 123 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 124 MEXICO BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 125 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 126 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 127 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 128 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 129 MEXICO RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 130 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 131 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 132 EUROPE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 133 EUROPE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 134 EUROPE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 EUROPE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 136 EUROPE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 137 EUROPE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 138 EUROPE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 139 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 140 EUROPE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 141 EUROPE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 142 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 143 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 144 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 145 EUROPE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 146 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 147 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 148 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 149 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 150 EUROPE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 151 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 152 GERMANY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 GERMANY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 154 GERMANY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 155 GERMANY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 156 GERMANY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 157 GERMANY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 158 GERMANY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 159 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 160 GERMANY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 161 GERMANY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 162 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 163 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 164 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 165 GERMANY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 166 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 167 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 168 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 169 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 170 GERMANY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 171 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 172 FRANCE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 173 FRANCE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 174 FRANCE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 175 FRANCE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 176 FRANCE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 177 FRANCE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 178 FRANCE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 179 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 180 FRANCE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 181 FRANCE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 182 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 183 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 184 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 185 FRANCE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 186 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 187 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 188 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 189 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 190 FRANCE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 191 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 192 U.K. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 193 U.K. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 194 U.K. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 195 U.K. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 196 U.K. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 197 U.K. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 198 U.K. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 199 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 200 U.K. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 201 U.K. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 202 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 203 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 204 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 205 U.K. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 206 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 207 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 208 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 209 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 210 U.K. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 211 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 212 ITALY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 213 ITALY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 214 ITALY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 215 ITALY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 216 ITALY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 217 ITALY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 218 ITALY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 220 ITALY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 221 ITALY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 222 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 223 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 224 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 225 ITALY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 226 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 227 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 228 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 229 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 230 ITALY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 231 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 232 SPAIN MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 233 SPAIN ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 234 SPAIN ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 235 SPAIN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 236 SPAIN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 237 SPAIN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 238 SPAIN COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 239 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 240 SPAIN ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 241 SPAIN TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 242 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 243 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 244 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 245 SPAIN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 246 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 247 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 248 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 249 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 250 SPAIN RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 251 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 252 RUSSIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 253 RUSSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 254 RUSSIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 255 RUSSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 256 RUSSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 257 RUSSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 258 RUSSIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 259 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 260 RUSSIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 261 RUSSIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 262 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 263 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 264 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 265 RUSSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 266 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 267 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 268 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 269 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 270 RUSSIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 271 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 272 SWITZERLAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 273 SWITZERLAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 274 SWITZERLAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 275 SWITZERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 276 SWITZERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 277 SWITZERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 278 SWITZERLAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 279 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 280 SWITZERLAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 281 SWITZERLAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 282 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 283 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 284 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 285 SWITZERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 286 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 287 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 288 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 289 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 290 SWITZERLAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 291 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 292 NETHERLAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 293 NETHERLAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 294 NETHERLAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 295 NETHERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 296 NETHERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 297 NETHERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 298 NETHERLAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 299 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 300 NETHERLAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 301 NETHERLAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 302 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 303 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 304 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 305 NETHERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 306 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 307 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 308 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 309 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 310 NETHERLAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 311 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 312 TURKEY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 313 TURKEY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 314 TURKEY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 315 TURKEY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 316 TURKEY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 317 TURKEY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 318 TURKEY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 319 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 320 TURKEY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 321 TURKEY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 322 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 323 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 324 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 325 TURKEY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 326 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 327 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 328 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 329 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 330 TURKEY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 331 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 332 BELGIUM MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 333 BELGIUM ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 334 BELGIUM ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 335 BELGIUM APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 336 BELGIUM BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 337 BELGIUM APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 338 BELGIUM COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 339 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 340 BELGIUM ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 341 BELGIUM TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 342 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 343 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 344 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 345 BELGIUM BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 346 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 347 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 348 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 349 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 350 BELGIUM RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 351 REST OF EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 352 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 353 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 354 ASIA-PACIFIC MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 355 ASIA-PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 356 ASIA-PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 357 ASIA-PACIFIC APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 358 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 359 ASIA-PACIFIC APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 360 ASIA-PACIFIC COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 361 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 362 ASIA-PACIFIC ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 363 ASIA-PACIFIC TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 364 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 365 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 366 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 367 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 368 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 369 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 370 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 371 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 372 ASIA-PACIFIC RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 373 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 374 CHINA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 375 CHINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 376 CHINA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 377 CHINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 378 CHINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 379 CHINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 380 CHINA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 381 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 382 CHINA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 383 CHINA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 384 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 385 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 386 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 387 CHINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 388 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 389 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 390 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 391 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 392 CHINA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 393 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 394 JAPAN MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 395 JAPAN ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 396 JAPAN ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 397 JAPAN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 398 JAPAN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 399 JAPAN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 400 JAPAN COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 401 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 402 JAPAN ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 403 JAPAN TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 404 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 405 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 406 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 407 JAPAN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 408 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 409 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 410 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 411 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 412 JAPAN RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 413 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 414 INDIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 415 INDIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 416 INDIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 417 INDIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 418 INDIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 419 INDIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 420 INDIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 421 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 422 INDIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 423 INDIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 424 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 425 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 426 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 427 INDIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 428 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 429 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 430 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 431 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 432 INDIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 433 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 434 AUSTRALIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 435 AUSTRALIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 436 AUSTRALIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 437 AUSTRALIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 438 AUSTRALIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 439 AUSTRALIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 440 AUSTRALIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 441 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 442 AUSTRALIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 443 AUSTRALIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 444 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 445 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 446 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 447 AUSTRALIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 448 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 449 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 450 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 451 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 452 AUSTRALIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 453 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 454 SOUTH KOREA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 455 SOUTH KOREA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 456 SOUTH KOREA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 457 SOUTH KOREA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 458 SOUTH KOREA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 459 SOUTH KOREA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 460 SOUTH KOREA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 461 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 462 SOUTH KOREA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 463 SOUTH KOREA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 464 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 465 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 466 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 467 SOUTH KOREA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 468 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 469 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 470 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 471 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 472 SOUTH KOREA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 473 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 474 SINGAPORE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 475 SINGAPORE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 476 SINGAPORE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 477 SINGAPORE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 478 SINGAPORE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 479 SINGAPORE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 480 SINGAPORE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 481 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 482 SINGAPORE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 483 SINGAPORE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 484 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 485 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 486 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 487 SINGAPORE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 488 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 489 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 490 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 491 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 492 SINGAPORE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 493 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 494 MALAYSIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 495 MALAYSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 496 MALAYSIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 497 MALAYSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 498 MALAYSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 499 MALAYSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 500 MALAYSIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 501 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 502 MALAYSIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 503 MALAYSIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 504 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 505 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 506 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 507 MALAYSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 508 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 509 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 510 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 511 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 512 MALAYSIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 513 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 514 PHILIPPINES MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 515 PHILIPPINES ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 516 PHILIPPINES ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 517 PHILIPPINES APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 518 PHILIPPINES BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 519 PHILIPPINES APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 520 PHILIPPINES COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 521 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 522 PHILIPPINES ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 523 PHILIPPINES TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 524 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 525 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 526 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 527 PHILIPPINES BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 528 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 529 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 530 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 531 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 532 PHILIPPINES RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 533 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 534 INDONESIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 535 INDONESIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 536 INDONESIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 537 INDONESIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 538 INDONESIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 539 INDONESIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 540 INDONESIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 541 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 542 INDONESIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 543 INDONESIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 544 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 545 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 546 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 547 INDONESIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 548 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 549 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 550 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 551 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 552 INDONESIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 553 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 554 THAILAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 555 THAILAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 556 THAILAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 557 THAILAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 558 THAILAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 559 THAILAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 560 THAILAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 561 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 562 THAILAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 563 THAILAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 564 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 565 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 566 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 567 THAILAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 568 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 569 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 570 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 571 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 572 THAILAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 573 REST OF ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 574 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 575 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 576 SOUTH AMERICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 577 SOUTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 578 SOUTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 579 SOUTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 580 SOUTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 581 SOUTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 582 SOUTH AMERICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 583 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 584 SOUTH AMERICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 585 SOUTH AMERICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 586 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 587 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 588 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 589 SOUTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 590 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 591 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 592 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 593 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 594 SOUTH AMERICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 595 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 596 BRAZIL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 597 BRAZIL ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 598 BRAZIL ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 599 BRAZIL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 600 BRAZIL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 601 BRAZIL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 602 BRAZIL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 603 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 604 BRAZIL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 605 BRAZIL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 606 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 607 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 608 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 609 BRAZIL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 610 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 611 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 612 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 613 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 614 BRAZIL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 615 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 616 ARGENTINA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 617 ARGENTINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 618 ARGENTINA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 619 ARGENTINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 620 ARGENTINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 621 ARGENTINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 622 ARGENTINA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 623 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 624 ARGENTINA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 625 ARGENTINA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 626 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 627 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 628 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 629 ARGENTINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 630 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 631 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 632 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 633 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 634 ARGENTINA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 635 REST OF SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 636 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 637 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 638 MIDDLE EAST AND AFRICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 639 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 640 MIDDLE EAST AND AFRICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 641 MIDDLE EAST AND AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 642 MIDDLE EAST AND AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 643 MIDDLE EAST AND AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 644 MIDDLE EAST AND AFRICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 645 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 646 MIDDLE EAST AND AFRICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 647 MIDDLE EAST AND AFRICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 648 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 649 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 650 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 651 MIDDLE EAST AND AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 652 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 653 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 654 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 655 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 656 MIDDLE EAST AND AFRICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 657 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 658 SOUTH AFRICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 659 SOUTH AFRICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 660 SOUTH AFRICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 661 SOUTH AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 662 SOUTH AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 663 SOUTH AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 664 SOUTH AFRICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 665 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 666 SOUTH AFRICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 667 SOUTH AFRICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 668 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 669 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 670 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 671 SOUTH AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 672 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 673 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 674 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 675 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 676 SOUTH AFRICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 677 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 678 EGYPT MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 679 EGYPT ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 680 EGYPT ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 681 EGYPT APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 682 EGYPT BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 683 EGYPT APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 684 EGYPT COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 685 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 686 EGYPT ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 687 EGYPT TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 688 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 689 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 690 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 691 EGYPT BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 692 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 693 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 694 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 695 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 696 EGYPT RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 697 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 698 SAUDI ARABIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 699 SAUDI ARABIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 700 SAUDI ARABIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 701 SAUDI ARABIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 702 SAUDI ARABIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 703 SAUDI ARABIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 704 SAUDI ARABIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 705 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 706 SAUDI ARABIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 707 SAUDI ARABIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 708 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 709 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 710 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 711 SAUDI ARABIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 712 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 713 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 714 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 715 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 716 SAUDI ARABIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 717 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 718 U.A.E. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 719 U.A.E. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 720 U.A.E. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 721 U.A.E. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 722 U.A.E. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 723 U.A.E. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 724 U.A.E. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 725 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 726 U.A.E. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 727 U.A.E. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 728 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 729 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 730 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 731 U.A.E. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 732 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 733 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 734 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 735 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 736 U.A.E. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

Список рисунков

FIGURE 1 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SEGMENTATION

FIGURE 2 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SEGMENTATION

FIGURE 11 GROWING PREVALENCE OF COLD SORE INFECTION IS DRIVING THE GROWTH OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET FROM 2024 TO 2031

FIGURE 12 THE TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET IN 2024 AND 2031

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET

FIGURE 16 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, 2023

FIGURE 17 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)

FIGURE 18 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, CAGR (2024-2031)

FIGURE 19 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, 2023

FIGURE 21 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)

FIGURE 22 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 23 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 24 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, 2023

FIGURE 25 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, 2024-2031 (USD THOUSAND)

FIGURE 26 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, CAGR (2024-2031)

FIGURE 27 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 28 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, 2023

FIGURE 29 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, 2024-2031 (USD THOUSAND)

FIGURE 30 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, CAGR (2024-2031)

FIGURE 31 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, LIFELINE CURVE

FIGURE 32 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, 2023

FIGURE 33 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)

FIGURE 34 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, CAGR (2024-2031)

FIGURE 35 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 36 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, 2023

FIGURE 37 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 38 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, CAGR (2024-2031)

FIGURE 39 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 40 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, 2023

FIGURE 41 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, 2024-2031 (USD THOUSAND)

FIGURE 42 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 43 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, LIFELINE CURVE

FIGURE 44 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, 2023

FIGURE 45 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 46 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, CAGR (2024-2031)

FIGURE 47 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 48 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 49 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 50 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 51 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 52 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SNAPSHOT (2023)

FIGURE 53 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)

FIGURE 54 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)

FIGURE 55 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)

FIGURE 56 AISA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)

View Detailed Information

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

How big is the Cold Sore Treatment (for HSV 1 Virus) Market?

The Cold Sore Treatment (for HSV 1 Virus) Market size will be worth USD 1,501.88 million by 2031.

What is the growth rate of the Cold Sore Treatment (for HSV 1 Virus) Market?

The Cold Sore Treatment (for HSV 1 Virus) Market growth rate will be 6.6% by 2031.

What are the growth drivers of the Cold Sore Treatment (for HSV 1 Virus) Market?

Growing Prevalence of Cold Sore Infection and Growing Awareness about Cold Sore Symptoms and Treatment Options are the growth drivers of the Cold Sore Treatment (for HSV 1 Virus) Market.

What are the factors on which the Cold Sore Treatment (for HSV 1 Virus) Market research is based on?

The treatment type, route of administration, mode of purchase, strain type, drug type, population type, gender, end user, and distribution channel are the factors on which the Cold Sore Treatment (for HSV 1 Virus) Market research is based.

Which are the major companies in the Cold Sore Treatment (for HSV 1 Virus) Market?

The major companies in the Cold Sore Treatment (for HSV 1 Virus) Market are Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies, and Devirex AG.

Глобальный рынок лечения герпеса (вируса HSV 1) – тенденции отрасли и прогноз до 2031 года

Глобальный рынок лечения герпеса (вируса HSV 1) – тенденции отрасли и прогноз до 2031 года

Global Cold Sore Treatment For Hsv 1 Virus Market

CAGR : 6.60 %

Анализ и размер рынка лечения герпеса (вируса HSV 1)

Динамика мирового рынка лечения герпеса (вируса HSV 1)

Мировой рынок лечения герпеса (вируса HSV 1)

Региональный анализ/информация о мировом рынке лечения герпеса (вируса HSV 1)

Конкурентная среда и глобальный анализ доли рынка лечения герпеса (вируса HSV 1)

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Отчеты

Обзор рынка

Поддерживать

Решения

Глобальный рынок лечения герпеса (вируса HSV 1) – тенденции отрасли и прогноз до 2031 года

Глобальный рынок лечения герпеса (вируса HSV 1) – тенденции отрасли и прогноз до 2031 года

Global Cold Sore Treatment For Hsv 1 Virus Market

CAGR : 6.60 %

Анализ и размер рынка лечения герпеса (вируса HSV 1)

Динамика мирового рынка лечения герпеса (вируса HSV 1)

Мировой рынок лечения герпеса (вируса HSV 1)

Региональный анализ/информация о мировом рынке лечения герпеса (вируса HSV 1)

Конкурентная среда и глобальный анализ доли рынка лечения герпеса (вируса HSV 1)

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Просмотр связанных страниц